Earnings Call · Q2 FY2023·2023-08-09

Q2 23EPS +2.22%·Rev n/aQ1 23EPS +25.00%·Rev n/aQ4 22EPS +34.04%·Rev n/aQ3 22EPS +56.25%·Rev n/a⚠ consensus missing

Lantern Pharma Inc. LTRN

Nicole Leber — Investor Relations

Panna Sharma — Chief Executive Officer

David Margave — Chief Financial Officer

+7.1%1d on move date+7.0% vs SPY3d+2.8%5d−1.3%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more LTRN calls or request research access.

More LTRN calls Browse calls Request research access